From Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs:

msouza_cropped

msouza_cropped—

Photo of Praxis Precision Medicines CEO Marcio Souza. Photo by Praxis.

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
Navigating Challenges & Advancing Clinical Development: A Toolkit for Emerging Biotechs
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace

Sponsored · Whitepaper
Bridging the Diversity Gap with Decentralized Trials
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
PRA Health Sciences

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

Xconomy on Demand

We offer a number of ways to subscribe for free!